The role of USP19 in human diseases: from molecular function to clinical relevance
-
By
-
Qingsong Wang
-
Haonan Cao
-
Huan Wei
-
Xianmin Wang
-
Tongyong Luo
-
Jun Yin
-
June 26, 2026
-
Clinical Scorecard: The significance of USP19 in human health conditions: linking molecular mechanisms to clinical implications
At a Glance
| Category | Detail |
|---|
| Condition | USP19 dysregulation in malignancies and non-neoplastic diseases |
| Key Mechanisms | Regulates protein stability, immune signaling, and cellular stress responses through deubiquitination. |
| Target Population | Patients with malignancies and non-neoplastic diseases exhibiting aberrant USP19 expression. |
| Care Setting | Clinical and translational research environments. |
Key Highlights
- USP19 is involved in tumor proliferation, metastasis, and immune evasion.
- Aberrant expression of USP19 is linked to poor patient prognosis in various cancers.
- USP19 has potential as a diagnostic biomarker and treatment response predictor.
- Regulates inflammatory responses and is implicated in non-neoplastic diseases like liver injury.
- Small-molecule modulators targeting USP19 are in preclinical development.
Guideline-Based Recommendations
Diagnosis
- Consider USP19 expression levels as potential biomarkers for cancer prognosis.
Management
- Explore targeted therapies aimed at modulating USP19 activity in malignancies.
Monitoring & Follow-up
- Monitor USP19 levels in patients undergoing treatment for malignancies to assess response.
Risks
- Aberrant USP19 expression may contribute to tumor progression and treatment resistance.
Patient & Prescribing Data
Patients with malignancies and inflammatory diseases associated with USP19 dysregulation.
Targeted strategies against USP19 are under investigation but not yet clinically available.
Clinical Best Practices
- Integrate USP19 expression analysis in the diagnostic workup for certain cancers.
- Utilize USP19 as a prognostic tool in clinical settings.
Related Resources & Content
